ID   BPH-1
AC   CVCL_1091
SY   BPH1; Benign Prostatic Hyperplasia-1
DR   BTO; BTO:0001323
DR   CLO; CLO_0002022
DR   CLDB; cl7219
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473417
DR   cancercelllines; CVCL_1091
DR   Cell_Model_Passport; SIDM00964
DR   ChEMBL-Cells; CHEMBL3308186
DR   ChEMBL-Targets; CHEMBL2366131
DR   Cosmic; 924105
DR   Cosmic; 1995347
DR   Cosmic-CLP; 924105
DR   DepMap; ACH-001453
DR   DSMZ; ACC-143
DR   DSMZCellDive; ACC-143
DR   EGA; EGAS00001000978
DR   GDSC; 924105
DR   GEO; GSM827571
DR   GEO; GSM1374405
DR   GEO; GSM1669628
DR   IARC_TP53; 27687
DR   ICLC; HTL11006
DR   IGRhCellID; BPH1
DR   LINCS_HMS; 50005
DR   LINCS_LDP; LCL-2095
DR   Millipore; SCC256
DR   PharmacoDB; BPH1_107_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1091
DR   PubChem_Cell_line; CVCL_1091
DR   SKY/M-FISH/CGH; 1510
DR   Wikidata; Q54798059
RX   CelloPub=CLPUB00698;
RX   PubMed=7535634;
RX   PubMed=11304728;
RX   PubMed=11719443;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21248069;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://web.archive.org/web/20150602153427/http://capcelllines.ca:80/details.asp?id=132
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~50 hours (DSMZ=ACC-143).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.5%; East Asian, South=0.02%; South Asian=2.82%; European, North=66.48%; European, South=29.17% (PubMed=30894373).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
ST   Source(s): Cosmic-CLP; DepMap; DSMZ; Millipore; PubMed=11304728
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 9
ST   D18S51: 10,16
ST   D19S433: 12,15
ST   D21S11: 28,32.2
ST   D2S1338: 17
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 10,15
ST   FGA: 21,24 (DepMap; DSMZ; PubMed=11304728)
ST   FGA: 24 (Millipore)
ST   Penta D: 9,14
ST   Penta E: 7,10
ST   TH01: 6,7
ST   TPOX: 8,12
ST   vWA: 17
DI   NCIt; C2897; Benign prostatic hyperplasia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   68Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
//
RX   PubMed=7535634; DOI=10.1007/BF02631333;
RA   Hayward S.W., Dahiya R., Cunha G.R., Bartek J., Deshpande N.,
RA   Narayan P.;
RT   "Establishment and characterization of an immortalized but
RT   non-transformed human prostate epithelial cell line: BPH-1.";
RL   In Vitro Cell. Dev. Biol. Anim. 31:14-24(1995).
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//
RX   PubMed=11719443;
RA   Phillips J.L., Hayward S.W., Wang Y.-Z., Vasselli J., Pavlovich C.P.,
RA   Padilla-Nash H.M., Pezullo J.R., Ghadimi B.M., Grossfeld G.D.,
RA   Rivera A., Linehan W.M., Cunha G.R., Ried T.;
RT   "The consequences of chromosomal aneuploidy on gene expression
RT   profiles in a cell line model for prostate carcinogenesis.";
RL   Cancer Res. 61:8143-8149(2001).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21248069; DOI=10.1158/0008-5472.CAN-10-1998;
RA   Li Y.-M., Alsagabi M., Fan D.-H., Bova G.S., Tewfik A.H., Dehm S.M.;
RT   "Intragenic rearrangement and altered RNA splicing of the androgen
RT   receptor in a cell-based model of prostate cancer progression.";
RL   Cancer Res. 71:2108-2117(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//